← Volver a la portada
Estados Unidos · Actualidad general · Newsweek

Researchers Studied Two Alzheimer’s Groups. One Brain Difference Stood Out

Publicado por Newsweek · Estados Unidos hace 9 h
Researchers Studied Two Alzheimer’s Groups. One Brain Difference Stood Out - Newsweek featured image
Researchers Studied Two Alzheimer’s Groups. One Brain Difference Stood Out - Newsweek featured image · Newsweek

Resumen detallado

Alzheimer's patients can have different biological profiles, but scientists have found something that could be constant.

There may be one constant in Alzheimer’s disease, despite the different biological profiles seen among patients, with that being similar patterns of reduced activity in key areas of the brain.

That is one of the findings from a new study which examined how blood-brain barrier dysfunction may be linked to changes in brain metabolism, and what harm reduced brain metabolism could do. While two groups of assessed Alzheimer’s patients showed similar reductions in glucose metabolism, researchers found that the biological factors associated with those changes differed, pointing to potentially distinct pathways of brain dysfunction.

“Alzheimer's disease is often associated with the pathological accumulation of amyloid plaques and tau tangles, but this study highlights the potential importance of blood-brain barrier dysfunction in a certain subset of patients,” Dr. Amy Reichelt, a behavioral neuroscientist and Amble Health advisor, told Newsweek.

Newsweek reached out via email to the study’s authors, Professor Alessandro Martorana and Dr. Chiara Bonomi, for more information.

Alzheimer’s is characterized by accumulations of amyloid-beta and tau proteins that contribute to neuronal dysfunction and cognitive decline. However, patients do not always have the same biological profile.

The findings, published in Aging, examined 66 patients along the Alzheimer’s disease continuum while 41 cognitively healthy participants made up a control group.

Researchers then separated the patients into two groups using biomarkers for amyloid accumulation, tau pathology and neurodegeneration. One group showed evidence of all three abnormalities. The other showed only amyloid pathology and neurodegeneration without elevated phosphorylated tau.

Using advanced imaging, researchers were able to measure levels of glucose metabolism, an indicator of brain activity. Cerebrospinal fluid biomarkers were also used to assess Alzheimer’s-related changes, while the ratio of albumin in cerebrospinal fluid to serum…

Th…

Inicio del artículo, extracto de Newsweek. Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en Newsweek Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.newsweek.com)

También te puede interesar